Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 14/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 11/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4953629 | 0.85 | SCN9A (0.48) | SCN9ASCN5AS1PR1S1PR3S1PR5 | |
| SCHEMBL2787545 | 0.85 | SCN9A (0.58) | SCN9ASCN5AS1PR1CYP3A4CYP2C9 | |
| SCHEMBL2804078 | 0.81 | SCN9A (0.49) | SCN9ASCN5AS1PR1CYP3A4CYP2C9 | |
| SCHEMBL30223647 | 0.76 | S1PR1 (0.56) | S1PR1S1PR3S1PR5 | |
| SCHEMBL16591182 | 0.76 | S1PR1 (0.56) | S1PR1S1PR3S1PR5 | |
| SCHEMBL364675 | 0.74 | SCN9A (0.48) | SCN9ASCN5A | |
| SCHEMBL14089851 | 0.73 | S1PR1 (0.53) | SCN9ASCN5AS1PR1S1PR3S1PR5 | |
| SCHEMBL2807560 | 0.73 | S1PR1 (0.58) | S1PR1S1PR3S1PR5MAP4K4PRKCD | |
| SCHEMBL16591380 | 0.72 | S1PR1 (0.50) | S1PR1S1PR3S1PR5MAP4K4MINK1 | |
| SCHEMBL1420273 | 0.71 | S1PR1 (0.52) | S1PR1S1PR3S1PR5MAP4K4PRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | SCN9A 2891/4885SCN5A 2239/4885S1PR1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.